HUMAN RECOMBINANT INTERLEUKIN 4 INDUCES
Fcε RECEPTORS (CD23) ON
NORMAL HUMAN B LYMPHOCYTES

BY T. DEFRANCE,* J. P. AUBRY,* F. ROUSSET,* B. VANBERVLIET,*
J. Y. BONNEFOY,* N. ARAI,† Y. TAKEBE,‡ T. YOKOTA,‡ F. LEE,‡
K. ARAI,† J. DE VRIES,* AND J. BANCHEREAU*

From *UNICET Laboratory for Immunological Research, Dardilly 69572, France; and
†DNAX, Research Institute of Molecular and Cellular Biology, Palo Alto, California 94304

We have recently reported (1) the isolation of a cDNA sequence coding for
human IL-4 B cell stimulatory factor 1 (BSF1).1 This lymphokine is a T cell-
derived glycoprotein consisting of 129 amino acids with two potential N-glyco-
sylation sites. Human IL-4 is able to induce the proliferation of activated B
lymphocytes (Defrance, T., B. Vanbervliet, J. P. Aubry, et al., manuscript
submitted for publication) and activated T lymphocytes (Spits, H., H. Yssel, Y.
Takebe, et al. manuscript submitted for publication). During the course of our
studies aimed at characterizing the phenotype of the B lymphocyte population
proliferating in response to IL-4, we studied the expression of several activation
markers. The most striking phenotypic modification mediated by IL-4 was the
induction on B lymphocytes of the low-affinity receptor (Rε) for IgE
(FcεRε/CD23) (2, 3), as determined by the binding of the FcεRε/CD23-specific
mAb 25. We also show in this report that IFN-γ specifically inhibits the IL-4-
mediated induction of FcεRε/CD23.

Materials and Methods

Reagents. Insolubilized rabbit anti-human IgM (Bio-Rad Laboratories, Richmond,
CA) was used at the final concentration of 5 μg/ml. The anti FcεRε (CD23 antigen)-
specific mAb 25 was produced after immunizing mice with RPMI 8866 cells (2). The
FITC-conjugated goat anti-mouse Ig used in the indirect immunofluorescence assays
was purchased from Grub (Vienna, Austria). OKT mAbs were from Ortho Diagnostic Systems
Inc. (Westwood, MA); Leu mAbs were from Becton Dickinson Monoclonal Center
(Mountain View, CA); B1, MO2, and MO1 were from Coulter Immunology (Hialeah,
FL).

Escherichia coli–derived rIFN-γ (107 IU/mg) was obtained from Schering Research,
Bloomfield, NJ. IL-4 was obtained as supernatants from COS-7 cells transfected with pcD
vector containing the human IL-4 cDNA clone (1). 1 U of IL-4 is defined as the amount
providing a half-maximal [3H]Tdr uptake in activated PHA blasts (1). Some experiments
were performed with purified IL-4. Mock preparations consisting of culture supernatants
of COS-7 cells transfected with a nonrelated cDNA were also used. Human rIL-2 was

† Abbreviations used in this paper: AET, aminoethylisothiouronium bromide; BCGF, B cell growth
factor; BSF1, B cell stimulatory factor 1; cBCGF, commercial BCGF; EBV LCL, EBV-transformed
lymphoblastoid cell lines; FcεRε, low-affinity receptor for IgE on lymphoid cells. FLS, forward light
scatter; PLS, perpendicular light scatter; PY, pyronin Y.

J. Exp. Med. © The Rockefeller University Press · 0022-1007/87/06/1459/09 $1.00
Volume 165 June 1987 1459-1467
obtained as *E. coli* lysates from Dr. R. Kastelein at DNAX and as a purified protein from Amgen Biologicals (Thousand Oaks, CA). Human rIL-1α was obtained from Dr. Zurawski at DNAX in the form of *E. coli* lysates. It was purified by SDS-PAGE and the IL-1 was eluted from its migration area in the gel by reverse electrophoresis. A commercial preparation of a low-molecular-weight B cell growth factor (BCGF) purified from the culture supernatants of PHA-stimulated PBL was obtained from Cellular Products Inc. (Buffalo, NY) and is referred to in the text as commercial BCGF (cBCGF). This preparation was free from IL-2 and IFN-γ activity, as determined by measurement of the [3H]-TdR uptake by the IL-2-dependent mouse T cell line CTLL-2 and an ELISA assay, respectively.

**B Cell Preparations and Cultures.** B cells were isolated either from tonsils or from blood cytopheresis residues. Mononuclear cells were separated by the standard Ficoll/Hypaque gradient method. Tonsil B cells were obtained by twice rosetting with amino ethyl isothiouronium bromide (AET)-treated SRBC, while blood B cells were submitted to a single rosetting with AET-treated SRBC followed by complement-mediated lysis of the remaining T cells with the use of anti-T3 (CD3), -T4 (CD4), -T8 (CD8), -T11 (CD2) mAbs. Depletion of blood monocytes, null cells and large granular lymphocytes was achieved by L-leucine methyl ester treatment according to the method described by Thiele et al. (4). The B cell–enriched populations obtained were typically >95% surface Ig-positive, >95% B1 antigen (CD20)-positive. <1% of the cells were positively stained by the T cell markers Leu-1, OKT4, OKT8, and OKT11 or by the monocyte markers: Leu-M3, MO1 (CD11), MO2 (CD14). <1% of the cells reacted with the NK cell markers: Leu-7 and Leu-11 (CD16).

Purified B cells were cultured at 10⁶ cells/ml in Iscove's medium enriched with 50 μg/ml human transferrin, 5 μg/ml bovine insulin, 0.5% BSA, oleic, linoleic, and palmitic acids (all from Sigma Chemical Co., St. Louis, MO) as described by Yssel et al. (5). 2% FCS was added to the medium.

**Analysis with a FACS.** Fluorescence analysis was performed with a FACS 440 (Becton Dickinson & Co., Sunnyvale, CA) equipped with a 5 W argon laser running at 488 nm, 0.5 W. Fluorescence parameters were collected using a built in logarithmic amplifier after gating on the combination of forward light scatter (FLS) and perpendicular light scatter (PLS), which was used to discriminate viable from nonviable cells.

**Cell Staining.** 4 × 10⁵ cells were incubated with 50 μl of the appropriately diluted mAb in 0.2-ml microtiter plate wells. After two washes with PBS containing 1% BSA, 0.01% sodium azide, cells were incubated with fluoresceinated F(ab')₂ fragments of goat anti-mouse Ig (Grub) for 30 min at 4°C. After three washes with PBS/BSA/azide, the cells were analyzed with the FACS.

**Simultaneous Measurement of RNA Content and Surface Antigen Expression.** The procedure used was adapted from Shapiro (6). 10⁶ cells/ml in PBS/1% BSA/0.01% sodium azide were incubated at 37°C for 45 min with 5 μM pyronin Y (PY; Aldrich Chemical Co., Milwaukee, WI). After centrifugation the cells were resuspended in cold PBS/BSA containing 4 μM PY (PBS/PY) and the mAb was added at the appropriate dilution. After an incubation of 30 min at 4°C the cells were washed twice in cold PBS/PY then resuspended in PBS/PY containing the fluorescent-conjugated goat anti-mouse Ig. After 30 min at 4°C, the cells were washed twice with cold PBS/PY and resuspended in PBS/PY. Analyses were performed within 15 min after staining. 15,000 cells were recorded. The green fluorescence (530 nm) specific for antibody staining is recorded with logarithmic amplification; the red fluorescence (>600 nm) specific for RNA staining is recorded with linear amplification.

**Results**

**IL-4 Specifically Induces the Expression of Fce Receptors/CD23 on Normal Human B Cells.** Highly purified tonsil B lymphocytes not stimulated or stimulated by insolubilized anti-IgM antibody were cultured with or without IL-4 (80 U/ml of a COS-7 cells transfection supernatant). After 24 or 48 h, cells were stained with
mAb 25, which is specific for the FcεRI/CD23. FACS histograms (Fig. 1) show that IL-4 is able to induce the expression of FcεRI/CD23 on nonactivated B cells but that the concomitant activation with anti-IgM antibodies increases the number of cells expressing FcεRI/CD23 as well as the intensity of FcεRI/CD23 expression on these cells. The nonactivated and the anti-IgM-activated B lymphocytes cultured with a mock COS-7 transfection supernatant did not significantly express FcεRI/CD23. The IL-4-induced expression of FcεRI/CD23 was confirmed by the binding of soluble IgE as assessed by flow cytometry after successive incubations of the cells with soluble IgE, an anti-IgE-specific mAb, and a FITC-labeled goat anti–mouse Ig conjugate (data not shown).

To determine the concentration that induces optimal FcεRI/CD23 induction, experiments were carried out with highly purified rIL-4 obtained from transfected COS-7 supernatants. Data in Fig. 2 show that the maximum expression of FcεRI/CD23 on anti-IgM-activated B cells is obtained with 700 pg/ml IL-4. The half-maximal induction of FcεRI/CD23 is obtained with ~176 pg/ml IL-4. It has been shown that activated B lymphocytes can proliferate in response to
INTERLEUKIN 4 INDUCES Fce RECEPTORS ON B CELLS

TABLE I

The Induction of Fce Receptor/CD23 on Normal B Cells Is Specific for IL-4

| Cytokine added   | FceR1<sup>+</sup> cells<sup>*</sup> |
|------------------|------------------------------------|
|                  | No activation | Anti-IgM activated |
|                  | %             |                   |
| 0                | 1 ± 1         | 3 ± 2             |
| Mock COS-7 (1%)  | 1 ± 1         | 1 ± 1             |
| IL-4 (80 U/ml)   | 20 ± 2        | 48 ± 4            |
| IL-1α (10 IU/ml) | 1 ± 1         | 2 ± 1             |
| IL-2 (20 IU/ml)  | 2 ± 1         | 1 ± 1             |
| IFN-γ (50 U/ml)  | 2 ± 1         | 2 ± 1             |
| IFN-γ (1,000 U/ml)| 4 ± 1        | 1 ± 1             |
| cBCGF (20%)      | 1 ± 1         | 1 ± 1             |
| UD 58 supernatant (5%)<sup>†</sup> | 2 ± 1 | 1 ± 1             |
| RPMI 8866 supernatant (20%)<sup>‡</sup> | 3 ± 2 | 3 ± 1             |
| HG 120 supernatant (10%)<sup>‡</sup> | 2 ± 1 | 1 ± 1             |

* Purified tonsil B cells were cultured for 48 h with the different cytokines and the FceR1/CD23 expression was assessed by flow cytometry using mAb 25.
† Supernatants from EBV-transformed cell lines containing BCGF activity as determined on anti-IgM-preactivated B cells but no IL-4, as determined by Northern analysis of isolated mRNA.
‡ Supernatant from an allogeneic IL-2-dependent T cell clone stimulated by its specific alloantigen and containing IL-2, IFN-γ, and BCGF activities.

many different lymphokines: IL-4 (Defrance, T., B. Vanbervliet, J. B. Aubrey, et al., manuscript submitted for publication), a low-molecular-weight BCGF (7), a high-molecular-weight BCGF (8), B cell–derived BCGFs (9, 10), IL-2 (11), IL-1 (12, 13), and IFN-γ (14, 15). However, IL-2, IL-1α, IFN-γ, a low-molecular-weight BCGF (cBCGF as obtained from Cellular Products Inc.), B cell–derived BCGF (as obtained from EBV-transformed B cell line supernatants), and a T cell clone supernatant (containing IL-2, IFN-γ, and BCGF) were unable to induce FceR1/CD23 expression (Table I). cBCGF that cooperates with IL-4 for the proliferation of activated B lymphocytes (Defrance, T., B. Vanbervliet, J. B. Aubrey, et al., manuscript submitted for publication) does not alter the induction of FceR1/CD23 on B cells (data not shown). The induction of FceR1/CD23 on normal B cells by IL-4 therefore seems to be a specific property of this lymphokine.

IFN-γ Inhibits the IL-4-induced FceR1/CD23 Expression. Since we failed to demonstrate the presence of FceR1/CD23-inducing activity in many T cell clone supernatants, including clone 2F1 from which the IL-4 cDNA was isolated, we investigated whether these T cell clone supernatants would contain factors inhibiting the IL-4-induced FceR1/CD23 expression on normal B lymphocytes. Recombinant lymphokines (IL-1, IL-2, IFN-γ) were assayed for their potential inhibitory action on the IL-4-induced FceR1/CD23 on B cells. The supernatant of clone 2F1 was found to strongly inhibit the IL-4-induced expression of FceR1/CD23 (data not shown). Among the three recombinant lymphokines
tested, IFN-γ was found to be a very potent inhibitor of the IL-4-induced FcεRI/CD23 expression, while neither IL-1 nor IL-2, nor cBCGF affected the induction of the FcεRI/CD23 (data not shown). Data in Fig. 3 show that concentrations of IFN-γ as low as 1 U/ml can partially inhibit the FcεRI/CD23 induction. Inhibition of IL-4-induced FcεRI/CD23 expression by IFN-γ was observed after 24 h of culture, but optimal inhibition was obtained after a 48-h incubation period. At optimal concentrations of IL-4, IFN-γ did not totally block the induction of FcεRI/CD23, while a complete inhibition of FcεRI/CD23 induction could be obtained with IFN-γ when suboptimal concentrations of IL-4 were used (data not shown). These data demonstrate that IFN-γ strongly antagonizes IL-4-induced FcεRI/CD23 expression on B cells.

IL-4 Induces the Expression of FcεRI/CD23 on B Cells in the G₀ Phase of the Cycle. Although IL-4 induces FcεRI/CD23 on tonsil B cells without preactivation, it has to be taken into account that the B cells studied here were obtained from donors with tonsillitis. This implies that a significant proportion of the B cells used were preactivated in vivo. To determine whether IL-4 induced FcεRI/CD23 on nonpreactivated B cells, the RNA content of the cells expressing FcεRI/CD23 was measured simultaneously. IL-4 alone (Fig. 4A) or in combination with insolubilized anti-IgM antibody (Fig. 4B) induced FcεRI/CD23 on a fraction of nonactivated B cells with low RNA contents but on an activated B cell fraction with relatively high RNA contents. The notion that preactivation of the B cells is not required for the induction of FcεRI/CD23 by IL-4 is also supported by the finding that IL-4 induced a strong expression of FcεRI/CD23 on peripheral blood B cells that are in the G₀ phase of the cell cycle, as well as on high-density tonsillar B cells obtained after Percoll-gradient centrifugation (data not shown).

Taken together these data strongly suggest that resting B cells express functional IL-4 receptors and demonstrate that not all the activated B cells express FcεRI/CD23 upon culture with IL-4.

Discussion

In the present study we have demonstrated that human rIL-4 (BSF 1) (1) is able to induce the expression of FcεRI/CD23 on human B lymphocytes. This has been demonstrated using the binding of the FcεRI/CD23 mAb 25 (2) or the binding of soluble IgE (data not shown). Concomitant B cell activation by
INTERLEUKIN 4 INDUCES Fcε RECEPTORS ON B CELLS

FIGURE 4. IL-4 induces FcεRI/CD23 on B cells in the G0 phase of the cycle. Purified tonsil B cells were cultured for 24 h with IL-4 (A) or IL-4 and anti-IgM antibody (B). Cells were stained with biotinylated mAb 25/FITC-conjugated avidin (green fluorescence, ordinate, log scale) and PY (red fluorescence, abscissa, linear scale) and were analyzed by double-fluorescence flow cytometry as described under Materials and Methods. The IL-4 was a COS-7 transfection supernatant used at 80 U/ml.

Insolubilized anti-IgM antibody resulted in enhanced FcεRI/CD23 induction by IL-4, suggesting an increased expression of IL-4 receptors on B cells. The finding that activation of the B cells enhanced IL-4-mediated FcεRI/CD23 induction suggested that IL-4 alone was inducing FcεRI/CD23 on the in vivo-preactivated B cells that are known to represent a significant proportion of tonsillar B lymphocytes. This however turned out not to be the case since double-fluorescence analysis carried out with mAb 25 and PY demonstrated that IL-4 induced FcεRI/CD23 on B cells containing low levels of RNA (a characteristic of cells in the G0 phase of the cycle) and on B cells with increased levels of RNA (G1 phase of the cycle).

The induction of FcεRI/CD23 on B cells seems to be specific for IL-4. rIL-2, rIFN-γ, rIL-1α, semipurified low-molecular-weight BCGF or the supernatant of EBV lymphoblastoid cell lines (LCL) containing BCGF activity but no IL-4 (as
determined by the absence of IL-4 mRNA in the cell line) were unable to induce FcεR₁/CD23 expression on normal B cells. Human rIL-4 has a FcεR₁/CD23-inducing activity comparable to the lymphokine purified from PHA-activated mononuclear cells supernatants studied by Suemura et al. (16). None of the tested lymphokines acted in concert or in synergy with IL-4, but interestingly, IFN-γ strongly inhibited the FcεR₁/CD23-inducing effect of IL-4. Strong inhibitory effects were observed at IFN-γ concentrations of 1 IU/ml. Although considerable blocking effects were obtained after 24 h of incubation with IL-4, the effect was most pronounced after 48 h. The mechanism by which IFN-γ blocks IL-4-induced FcεR₁/CD23 expression is presently under investigation. This inhibitory effect of IFN-γ is in line with the described antagonizing effects of murine IFN-γ on the proliferation of anti-IgM-activated B cells (17), the increase of class II MHC antigens on B cells, the increase in cell size (18, 19), and IgE and IgG1 production by LPS blasts (20) induced by IL-4. By contrast, the IL-4-induced proliferation of preactivated human B cells was stimulated by IFN-γ (Defrance, T., B. Vanbervliet, J. P. Aubrey, et al., manuscript submitted for publication).

At the present time the biological significance of the IL-4-induced FcεR₁/CD23 expression is unclear. The recent suggestion by Gordon et al. (21, 22) that the CD23 antigen may be the receptor for the low-molecular-weight BCGF (7) is worth considering, since it is in line with our data that indicate that IL-4 synergizes with the low-molecular-weight BCGF in inducing the proliferation of preactivated B cells (Defrance, T., B. Vanbervliet, J. P. Aubrey, et al., manuscript submitted for publication). The demonstration that IL-4 is able to induce (a) FcεR₁ on human B lymphocytes, (b) the proliferation of murine mast cells, and (c) IgE production by murine LPS blasts, demonstrates that IL-4 plays a major role in the IgE system at both the regulatory and the effector levels since it has been suggested that FcεR₁+ B cells play a major role in the regulation of IgE secretion (23). This hypothesis is confirmed by the recent finding that the in vivo injection of a mAb specific for mouse IL-4 (24) into Nippostrongylus brasiliensis–infected mice abrogates the induction of IgE production mediated by this treatment (25). The biological functions of FcεR₁/CD23 on B lymphocytes and the biological significance of its modulation by IL-4 and IFN-γ remain to be determined.

Summary

Human rIL-4 is able to induce the expression of low-affinity receptors for IgE (FcεR₁/CD23) on resting B lymphocytes, as determined by the binding of either the anti FcεR₁/CD23-specific mAb 25 or IgE. Stimulation of B cells with insolubilized anti-IgM antibody increases the number of cells expressing FcεR₁/CD23 upon culturing with IL-4 and enhances the level of FcεR₁/CD23 expression on these cells. FcεR₁/CD23 induction is specific for IL-4 since IL-1α, IL-2, IFN-γ, B cell–derived B cell growth factor (BCGF), and a low-molecular-weight BCGF were ineffective. IFN-γ strongly inhibited the induction of FcεR₁/CD23 by IL-4.

We thank P. Hoy, K. Yokota, E. Bower, and P. Meyerson for preparing IL-4 plasmid and transfecting COS-7 cells; Dr. A. Waitz for support and encouragement; Mrs. M. Vatan...
and Mr. B. Crouzet for editorial assistance; Dr. Le, Dr. Trotta, and Dr. Nagabhushan for providing us with highly purified rIL-4.

Received for publication 10 December 1986 and in revised form 12 February 1987.

References

1. Yokota, T., T. Otsuka, T. Mosmann, J. Banchereau, T. Defrance, D. Blanchard, J. de Vries, F. Lee, and K. Arai. 1986. Isolation and characterization of a human interleukin cDNA clone, homologous to mouse BSF-1, which expresses B cell and T cell stimulating activities. Proc. Natl. Acad. Sci. USA. 83:5894.

2. Bonnefoy, J. Y., J. P. Aubry, C. Peronne, J. Wijdenes, and J. Banchereau. 1987. Production and characterization of a monoclonal antibody specific for the human low affinity receptor for IgE: CD23 is a low affinity receptor for IgE. J. Immunol. In press.

3. Kikutani, H., S. Inui, R. Sato, E. L. Barsumian, H. Owaki, K. Yamasaki, T. Kalaho, N. Uchibayashi, R. R. Hardy, T. Hirano, S. Taunasawa, F. Sakiyama, M. Suemura, and T. Kishimoto. 1986. Molecular structure of the human lymphocyte receptor for Immunoglobulin E. Cell. 47:657.

4. Thiele, D. L., M. Kuvosaka, and P. E. Lipsky. 1983. Phenotype of the accessory cell necessary for antigen-stimulated T and B cell responses human peripheral blood: delineation by its sensitivity to the lysosomotropic agent, t-leucine methyl ester. J. Immunol. 131:2282.

5. Yssel, H., J. E. de Vries, M. Koken, W. Van Blitterswijk, and H. Spits. 1984. Serum-free medium for generation and propagation of functional human cytotoxic and helper T cell clones. J. Immunol. Methods. 72:219.

6. Shapiro, H. M. 1981. Flow cytometric of DNA and RNA content in intact cells stained with Hoechst 33342 and pyronin Y. Cytometry. 2:14.

7. Mehta, S. R., D. Conrad, R. Sandler, J. Morgan, R. Montagna, and A. Maizel. 1985. Purification of human B cell growth factor. J. Immunol. 135:3298.

8. Yoshizaki, K., T. Nakagawa, K. Fukunaga, T. Kaieda, S. Maruyama, S. Kishimoto, Y. Yamamura, and T. Kishimoto. 1985. Characterization of human B cell growth factor (BCGF) from cloned T cells or mitogen-stimulated T cells. J. Immunol. 139:1241.

9. Gordon, J., S. C. Ley, M. D. Melamed, L. S. English, and N. C. Hughes-Jones. 1984. Immortalized B lymphocytes produce B-cell growth factor. Nature (Lond.). 310:145.

10. Ambrus, J. L., and A. S. Fauci. 1985. Human B lymphoma cell line producing B cell growth factor. J. Clin. Invest. 75:752.

11. Zubler, R. H., J. W. Lowenthal, F. Erard, N. Hashimoto, R. Devos, and H. R. Macdonald. 1984. Activated B cells express receptors for and proliferate in response to pure interleukin 2. J. Exp. Med. 160:1170.

12. Howard, M. S., B. Mizel, L. Lachman, J. Ansel, B. Johnson, and W. E. Paul. 1983. Role of IL-1 in anti-immunoglobulin-induced B cell proliferation. J. Exp. Med. 157:1529.

13. Falkoff, R. J. M., J. L. Butler, C. A. Dinarello, and A. S. Fauci. 1984. Direct effects of a monoclonal B cell differentiation factor and of purified interleukin 1 on B cell differentiation. J. Immunol. 133:692.

14. Defrance, T., J. P. Aubry, B. Vanbervliet, and J. Banchereau. 1986. Human interferon-γ acts as a B cell growth factor in the anti-IgM antibody costimulatory assay but has no direct B cell differentiation activity. J. Immunol. 137:3861.

15. Romagnani, S., M. G. Givoizi, R. Biagiotti, F. Almerigogna, C. Mingari, E. Maggi, C. Liang, and L. Moretta. 1986. B cell growth factor activity of interferon γ.
Recombinant human interferon γ promotes proliferation of anti-μ activated human B lymphocytes. J. Immunol. 136:3513.

16. Suemura, M., H. Kikutani, E. L. Barsumian, Y. Hattori, S. Kishimoto, R. Sato, A. Maeda, H. Nakamura, H. Owaki, R. R. Hardy, and T. Kishimoto. 1986. Monoclonal anti-Fce receptor antibodies with different specificities and studies on the expression of Fce receptors on human B and T cells. J. Immunol. 137:1214.

17. Mond, J. J., F. D. Finkelman, C. Sarma, J. Ohara, and S. Serrate. 1985. Recombinant interferon γ inhibits the B cell proliferative response stimulated by soluble but not by Sepharose-bound anti-immunoglobulin antibody. J. Immunol. 135:2513.

18. Mond, J. J., J. Carman, C. Sarma, J. Ohara, and F. D. Finkelman. 1986. Interferon-γ suppresses B cell stimulation factor (BSF-1) induction of class II MHC determinants on B cells. J. Immunol. 137:3534.

19. Rabin, E. M., J. J. Mond, J. Ohara, and W. E. Paul. 1986. Interferon-γ inhibits the action of B cell stimulatory factor (BSF)-1 on resting B cells. J. Immunol. 137:1573.

20. Coffman, R. L., and J. Carty. 1986. A T cell activity that enhances polyclonal IgE production and its inhibition by interferon γ. J. Immunol. 136:949.

21. Gordon, J., M. Rowe, L. Walker, and G. Guy. 1986. Ligation of the CD23, p.45 (BLAST-2, EBVCS) antigen triggers the cell-cycle progression of activated B lymphocytes. Eur. J. Immunol. 16:1075.

22. Gordon, J., A. J. Webb, L. Walker, G. R. Guy, and M. Rowe. 1986. Evidence for an association between CD23 and the receptor for a low molecular weight B cell growth factor. Eur. J. Immunol. 16:1627.

23. Katz, D. H. 1984. Regulation of the IgE system: experimental and clinical aspects. Allergy (Copenh.). 39:81.

24. Ohara, J., and W. E. Paul. 1985. Production of a monoclonal antibody to and molecular characterization of B cell stimulatory factor-1. Nature (Lond.). 315:335.

25. Finkelman, F. D., I. M. Katona, J. F. Urban, Jr., C. M. Snapper, J. Ohara, and W. E. Paul. 1986. Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B cell stimulatory factor 1. Proc. Natl. Acad. Sci. USA. 83:9675.